DRUG INFORMATION JOURNAL

VOL.
19
1985

Official Publication of the
Drug Information Association

PERGAMON PRESS New York • Oxford • Beijing • Frankfurt • São Paulo
Sydney • Tokyo • Toronto

DRUG INFORMATION JOURNAL

Official Publication of the Drug Information Association

EDITOR-IN-CHIEF

Thomas W. Teal

Administrative Director, Drug Information Association

EDITORIAL BOARD

Term ends December 31, 1985

Robert V. Cuddihy, *Oxford Research International*
Edward Dietrich, *Merck Sharp & Dohme*
Saul L. Gitomer, *Marion Laboratories*
Richard A. Guarino, MD, *Oxford Research International*
Daniel Hussar, PhD, *Philadelphia College of Pharmacy & Science*
Judith K. Jones, MD, PhD, *U.S. Food and Drug Administration*
Charles Leighton, MD, *Merck Sharpe & Dohme*
Patricia M. O'Brien, *Pharmaceutical Manufacturers Association*
Peter H. Rheinstein, MD, JD, *U.S. Food and Drug Administration*
Arthur Wykes, PhD, *National Library of Medicine*

Term ends December 31, 1986

George A. Braun, PhD, *Johnson & Johnson*
Vera C. Glocklin, PhD, *U.S. Food and Drug Administration*
Raymond H. Kahn, PhD, *Scripps Clinic and Research Foundation*
Louise S. Kaufman, PhD, *Merck & Company*
Gary G. Koch, PhD, *University of North Carolina*
Steven R. Moore, MPH, *U.S. Food and Drug Administration*
Stephen W. Schondelmeyer, PharmD, PhD, *Purdue University*
Michael J. Zelesko, PhD, *McNeil Pharmaceutical*

Editorial Office: Editor-in-Chief, *Drug Information Journal,* P.O. Box 113, Maple Glen, PA 19002, USA.

Publishing, Subscription, and Advertising Offices: Pergamon Press, Inc., Fairview Park, Elmsford, NY 10523, USA; or Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 0BW, England.

Published Quarterly: Annual subscription rate (1986): US$80.00; Two-year rate (1986/87): US$152.00. Back issue and microform subscription information available upon request. All prices include surface postage and insurance.

Drug Information Association members receive the *Drug Information Journal* as part of their annual dues. The association is dedicated to the extension of modern technology in biomedical information and data processing as well as the encouragement of cooperative efforts among education, research, industrial, and government personnel to disseminate information of that type. For information concerning membership, please see the Membership Information Page elsewhere in this issue, or write to: Drug Information Association, P.O. Box 113, Maple Glen, PA 19002.

Copyright © 1985 Drug Information Association Inc. Printed in the USA

Copyright Notice: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electric, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

Photocopying information for users in the U.S.A.: The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $3.00 per copy per article is paid directly to the Copyright Clearance Center Inc., 27 Congress Street, Salem, MA 01970. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon office.

The Item-Fee Code for this publication is: 0092-8615/85 $3.00 + .00

Drug Information Journal, Vol. 19, pp. 509–517, 1985
Printed in the USA. All rights reserved.

0092-8615/85/$3.00 + .00
©1985 Drug Information Association Inc.

Contents
Volume 19, 1985

Volume 19, Number 1 1985

CONTENTS

Duilio Poggiolini	1	Formats, Organization, and Processing of Registration Dossiers in the EEC
Stephen G. Bryant, Brock G. Guernsey, William H. Doutre', Bruce Mansbridge, Seymour Fisher	7	Public Drug Information: A Telephone-Based Model for Patient Education
Fred Schneiweiss, Vincent A. Uthoff	13	Sample Size and Postmarketing Surveillance
Thomas W. Teal, Angela Liadis Dimmig	17	Adverse Drug Experience Management
C. Stewart Snoddy, Robert A. Michalak, Louise S. Kaufman	27	The Pyramid Concept
Alan Saltzman	35	Adverse Reaction Terminology Standardization: A Report of Schering-Plough's Use of the WHO Dictionary and the Formation of the WHO Adverse Reaction Terminology User's Group Consortium
Kenneth Palmer	43	Database Development of a Clinical Trial
Sanford P. Sher, Carol Aserinsky, James Stuart, Lois Bird	49	Toxicity Test Registry: An Online Entry and Retrieval System

VOL.
19
1985

Gary R. Gallo **Albert Wertheimer**	57	An International Survey of Drug Information Centers
Jerzy L. Bem **Teresa Challoner**	63	Use of Microcomputers for Data Entry and Collection in a Multicentric Clinical Trial
Steven P. Vaitonis **James C. Swanger**	69	An Introduction to G. D. Searle's Biology Reporting System (BRS)
John M. Fischer	75	Effect of Ten Specific Questions on Nationwide Drug Information Center Activity
Murty Arisetty	81	Team-Based Approach to Clinical Data Processing
	I	Software Survey Section: *Clinical Research System (CRS); Quizmaster*

Volume 19, Number 2 1985

CONTENTS

Patrick E. Ciccone	85	Introduction and Commentary
	89	Workshop Session Chairpersons and Speakers
		SESSION I: LEGAL, REGULATORY, AND PROCEDURAL ISSUES
Craig E. Hammes	93	Introduction to Session I
Peter D. Bewley	95	Switching—The Triple Threat from Tylenol To Ibuprofen
William E. Gilbertson	101	The OTC Drug Review—Switch Without Regulation or Application
Charles N. Jolly	111	To Switch or not to Switch? GRAS/GRAE is Still the Question
Ann H. Wion	119	Rx-to-OTC Switch—The Process and Procedures

	127	Questions and Answers After Session I
		SESSION II: THE SELECTION OF SWITCH CANDIDATES–INDUSTRY, FDA, AND SCIENTIFIC PERSPECTIVES
John A. Scarlett	131	Introduction to Session II
Lawrence F. Haverkost	133	How Industry Assesses and Picks Suitable Candidates for Switch
Peter H. Rheinstein	139	Criteria Used by the FDA to Determine What Classes of Drugs are Appropriate Switch Candidates
Hugh H. Tilson	143	Use of Adverse Reaction Data Bases and Making Risk Assessments of Proposed Switch Candidates
	151	Questions and Answers After Session II
		SESSION III: THE IMPACT OF SWITCH ON THE PUBLIC
Albert G. Eckian	153	Introduction to Session III
Donald M. Vickery	155	A Medical Perspective
Mary M. Heslin	159	A Consumer Perspective
Collot Guerard	163	The Impact of Advertising and Its Regulation–A Federal Trade Commission Perspective
	173	Questions and Answers After Session III
		SESSION IV: WHAT COMES AFTER THE Rx-TO-OTC SWITCH?
Jerome A. Halperin	177	Introduction to Session IV
Clement Bezold	179	What Happens When Most Drugs are OTC?
Stephen W. Schondelmeyer	185	Pharmacists, Pharmaceuticals, and Drug Information in the 21st Century
Peter Barton Hutt	195	Drugs for Self-Medication in the Future: Their Source and the Social, Political, and Regulatory Climate

VOL. 19 1985

201 Questions and Answers After Session IV

I Software Survey Section

Volume 19, Number 3 **SPECIAL ISSUE** 1985
International Adverse Reaction Surveillance

CONTENTS

Judith K. Jones 205 Foreword and Acknowledgements

207 DIA International Adverse Reactions Surveillance Conference Planning Group

I. INTERNATIONAL DRUG SURVEILLANCE: STATUS AND FUTURE NEEDS

Mark Novitch 209 Keynote Address: International Adverse Reaction Surveillance

John Dunne 213 The World Health Organization View

Jan Koch-Weser 217 International Aspects of Spontaneous Reporting of Adverse Drug Reactions

Dorothy B. Windhorst 223 Electronic Records of Adverse Drug Reactions: Should They be Pooled?

Gerald A. Faich 227 International Drug Surveillance

William W. Vodra 231 Regulatory Considerations Regarding International Post-Marketing Surveillance

II. POST-MARKETING SURVEILLANCE: DRUG EPIDEMIOLOGY RESOURCES AND STUDIES

Hershel Jick 237 The Boston Collaborative Drug Surveillance Program and the Puget Sound Health Maintenance Organization

William D. Finkle 243 Studies of Drug Effects within the Kaiser Foundation Health Plan: Southern California Region

M. Lee Morse 249 The COMPASS Data Base

Linda M. Strand	253	Drug Epidemiology Resources and Studies: The Saskatchewan Data Base
James F. Fries	257	The ARAMIS (American Rheumatism Association Medical Information System) Post-Marketing Surveillance Program
Lynn Rosenberg	263	Post-Marketing Surveillance: The Approach of the Drug Epidemiology Unit
Faye A. Luscombe	269	Methodologic Issues in Pharmacy-Based Post-Marketing Surveillance
Hugh H. Tilson	275	Methodologic Issues in Post-Marketing Surveillance: Pharmaceutical Industry's View – Burroughs Wellcome
Diane Chen	285	Discussion Panel: International Issues in Post-Marketing Surveillance
		III. MANAGEMENT OF ADVERSE REACTION REPORTS
Charles Anello	291	Management of ADR Reports at the FDA
Wayne M. Turner	295	FDA Processing of ADR Reports
Gregory V. Brolund	299	The FDA Adverse Reaction Report Data Base
Elmer R. Gabrieli **John D. E. Gabrieli** **T. John Rosen**	305	Automated Monitoring of Adverse Drug Reactions
Arnold J. Gordon	319	Numerators, Denominators, and Other Holy Grails: Management and Interpretation of Worldwide Safety Data
		IV. ADVERSE REACTIONS ESTABLISHED MONITORING CENTERS AND IN DEVELOPING COUNTRIES
John McEwen **Bodizar Vhrovac**	329	Panel on Management of ADR Reports in Selected National Centers
Enrique Fefer	345	Developing National Systems: An Overview
Aida LeRoy	347	Developing National Systems: Experience in Selected Latin American Countries

VOL. 19 1985

Joan-Ramon Laporte 351 Developing National Systems: Spain as a Model

V. ADVERSE REACTIONS IN THE MEDICAL LITERATURE

Jan Venulet 357 Informativity of Adverse Drug Reactions Data in Medical Publications

VI. COMMUNICATION OF ADR EXPERIENCE: WHO, INDUSTRY AND REGULATORY EXPERIENCE

Suzan M. Streichenwein 367 Communication of ADR Information: Views from the Pharmaceutical Industry

Charles Thayer 371 Communication on ADR Information: The Experience at Hoechst

Win Castle
Arthur Baker 375 Communication of ADR Information: The Viewpoint of a British Company

C. Stewart Snoddy, Jr. 381 Communication of ADR Information: The Merck Experience

Kjell Strandberg 385 Experiences from the WHO Collaborating Centre for International Drug Monitoring

John Dunne 391 Final Discussion

I Software Survey Section: *RECOMBINANT TOOLKIT*

Volume 19, Number 4 1985
Special Issue: Geriatric Drug Testing and Development – Practical Applications

CONTENTS

William B. Abrams 395 Introduction

T. Franklin Williams 397 Drugs and the Elderly

Stuart L. Nightingale 401 Food and Drug Administration's Considerations in Geriatric Drug Testing

Barry Reisberg
Steven H. Ferris
Thomas Crook 405 Guidelines for Drug Trials in the Treatment of Age-Associated Cognitive Decline and Alzheimer's Disease

W. McFate Smith Thomas M. Vogt Christine Curtis Ireland Dennis Black	421	Resources in Geriatric Drug Research
Robert N. Butler	429	Clinical Trial Management of Subjects
Robert E. Vestal	435	Methodological Considerations for Geriatric Drug Testing (Phase 1 and 2 Trials)
Richard A. Guarino	447	Organization and Development of Clinical Trial Protocols and Research Methodology in Geriatric Drug Testing: Phase 3 Studies (Dementia)
Robert T. O'Neill	453	Statistical Considerations in Geriatric Drug Testing
Judith K. Jones	459	Adverse Drug Reaction Considerations in Geriatric Drug Research
Lawrence E. Klein	469	Adverse Drug Reactions in the Elderly
Vijaya L. Melnick	475	Special Considerations in Geriatric Research: Ethical and Legal Issues
Robert Temple	483	Food and Drug Administration's Guidelines for Clinical Testing of Drugs in the Elderly
F. Gilbert McMahon	487	Academic Perspective of Clinical Testing of Drugs in the Elderly
William R. Darrow	491	Industry Perspective on Geriatric Drug Testing
Judith Brown	497	Consumer Perspective on Clinical Testing of Drugs in the Elderly
Susan D. Abbott	501	Consumer Response
George Thomas Beall	503	Speaking for the Elderly
	507	Index to Volume 19, 1985
	I	Software Survey Section: *CLINTRIAL*

VOL.
19
1985

Author Index
Volume 19, 1985

Abbott SD, 501
Abrams WB, 395
Arisetty M, 81
Aserinsky C, 49

Beall GT, 503
Bem JL, 63
Bewley PD, 95
Bezold C, 179
Bird L, 49
Black D, 421
Brown J, 499
Bryant SG, 7
Butler RN, 429

Challoner T, 63
Ciccone PE, 85
Crook T, 405

Darrow WR, 491
Dimmig AL, 17
Doutré, WH, 7

Eckian AG, 153

Ferris SH, 405
Fischer JM, 75
Fisher S, 7

Gallo GR, 57
Gilbertson WE, 101
Guarino RA, 447
Guerard C, 163
Guernsey BG, 7

Halperin JA, 177
Hammes CE, 93
Haverkost LF, 133
Heslin MM, 159
Hutt PB, 195

Ireland CC, 421

Jolly CN, 111
Jones JK, 459

Kaufman LS, 27
Klein LE, 469

Mansbridge B, 7
McMahon FG, 487
Melnick VL, 475
Michalak RA, 27

Nightingale SL, 401

O'Neill RP, 453

Palmer K, 43
Poggiolini D, 1

Reisberg B, 405
Rheinstein PH, 139

Saltzman A, 35
Scarlett JA, 131
Schneiweiss F, 13
Schondelmeyer SW, 185
Sher SP, 49
Smith WM, 421
Snoddy CS, 27
Stuart J, 49
Swanger JC, 69

Teal TW, 17
Temple R, 483
Tilson HH, 143

Uthoff VA, 13

Vaitonis SP, 69
Vestal RE, 435
Vickery DM, 155
Vogt TM, 421

Wertheimer A, 57
Williams TF, 397
Wion AH, 119

VOL. 19 1985